医薬品有効成分(API)の世界市場予測(〜2025):種類別(革新型、ジェネリック)、メーカー別(キャプティブ、マーチャント)、合成別(合成、バイオテクノロジー)、製品別(ワクチン、ホルモン)、医薬品別(OTC、Rx)、用途別(糖尿病、腫瘍、CVD)

◆英語タイトル:Active Pharmaceutical Ingredient (API) Market by type (Innovative, generic), manufacturer (captive, merchant), synthesis (synthetic, biotech), by product (vaccines, Hormones), drug (OTC, Rx), application (Diabetes, oncology, CVD) - Global Forecast to 2025
◆商品コード:PH 1262
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年9月30日
◆ページ数:320
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥534,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Marketsandmarkets社は医薬品有効成分(API)の世界市場が2020年1873億ドルから2025年2483億ドルまで、年平均5.8%成長すると展望しています。本調査レポートでは、医薬品有効成分(API)の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(革新的医薬品有効成分、ジェネリック医薬品有効成分)分析、製造業者別(クォーツ、メタリック)分析、合成タイプ別(合成有効成分、バイオテクノロジー有効成分)分析、医薬品種類別(処方薬、市販薬)分析、治療用途別(伝染病、腫瘍、糖尿病、心血管疾患、疼痛管理)分析、地域別分析、競争状況、企業情報など、以下の構成でお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・医薬品有効成分(API)の世界市場規模:種類別(革新的医薬品有効成分、ジェネリック医薬品有効成分)
・医薬品有効成分(API)の世界市場規模:製造業者別(クォーツ、メタリック)
・医薬品有効成分(API)の世界市場規模:合成タイプ別(合成有効成分、バイオテクノロジー有効成分)
・医薬品有効成分(API)の世界市場規模:医薬品種類別(処方薬、市販薬)
・医薬品有効成分(API)の世界市場規模:治療用途別(伝染病、腫瘍、糖尿病、心血管疾患、疼痛管理)
・医薬品有効成分(API)の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period.” Growth in the active pharmaceutical ingredients market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.

“Biotech APIs segment is expected to grow at the highest CAGR during the forecast period”
On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in the demand for monoclonal antibodies and their similarity with the natural biological compounds found in the human body influence the growth of this segment.

“Monoclonal antibodies segment is expected to account for the largest share of the global APIs market, by product type.”
Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones, cytokines, fusion proteins, therapeutic enzymes, vaccines and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the APIs market. Large share of monoclonal antibodies is due to their rising application in oncology and other therapeutic areas, increase in number of FDA approvals for innovative biopharmaceutical products and increasing investments and technical advances in R&D for development of various novel products.

“North America will dominate the market during the forecast period.”
Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, andRest of the World. In 2019, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia. . The major factors driving the overall growth of the APIs market in this region include the growing prevalence of preventable chronic diseases, increasing government emphasis on generic drugs, escalating demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 37%, Tier 2: 22%, and Tier 3: 41%
• By Designation – C-level: 25%, D-level: 20%, and Others: 55%
• By Region – North America: 40%, Europe: 27%, Asia: 20%, and RoW: 13%

List of Companies Profiled in the Report
• Pfizer, Inc. (US)
• Novartis Internationla AG (Switzerland)
• Sanofi (France)
• Boehringer Ingelheim (Germany)
• Bristol-Myers Squibb (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eli Lilly and Company (US)
• GlaxoSmithKline plc (UK)
• Merck & Co., Inc. (US)
• Mylan N.V. (US)
• AbbVie Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AstraZeneca (UK)
• Cipla, Inc. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• API Pharma Tech (India)
• BDR Pharmaceuticals Internationals Pvt. Ltd. (India)
• Sreepathi Pharmaceuticals Limited (India)
• Shilpa Medicare Limited (India)

Research Coverage:
This report provides a detailed picture of the global active pharmaceutical ingredients market. It aims at estimating the size and future growth potential of the market across different segments, such as type, type of manufacturer, type of synthesis, type of drug, application and region.. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total active pharmaceutical ingredients market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on active pharmaceutical ingredients offered by the top 25 players in the active pharmaceutical ingredients market. The report analyses the active pharmaceutical ingredients market based on the type, type of manufacturer, type of synthesis, type of drug, application and region..
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various active pharmaceutical ingredients across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the active pharmaceutical ingredients market.

【レポートの目次】

1 INTRODUCTION 51
1.1 OBJECTIVES OF THE STUDY 51
1.2 MARKET DEFINITION 51
1.3 MARKET SCOPE 52
1.3.1 MARKETS COVERED 52
FIGURE 1 MARKET SEGMENTATION 52
1.3.2 YEARS CONSIDERED FOR THE STUDY 53
1.4 CURRENCY 53
1.5 LIMITATIONS 53
1.6 STAKEHOLDERS 54
1.7 SUMMARY OF CHANGES 54
2 RESEARCH METHODOLOGY 55
2.1 RESEARCH DATA 55
FIGURE 2 RESEARCH DESIGN 55
2.1.1 SECONDARY SOURCES 56
2.1.1.1 Key data from secondary sources 56
2.1.2 PRIMARY SOURCES 57
2.1.2.1 Primary sources 57
2.1.2.2 Key data from primary sources 58
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 58
2.2 MARKET SIZE ESTIMATION 59
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 59
FIGURE 5 MARKET SIZE ESTIMATION: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 59
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 62
FIGURE 6 DATA TRIANGULATION METHODOLOGY 62
2.4 MARKET SHARE ESTIMATION 63
2.5 ASSUMPTIONS FOR THE STUDY 63
3 EXECUTIVE SUMMARY 64
FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020 VS. 2025 (USD BILLION) 64
FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2020 VS. 2025 (USD BILLION) 65
FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020 VS. 2025 (USD BILLION) 65
FIGURE 10 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION) 66
FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020 VS. 2025 (USD BILLION) 67
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL
INGREDIENTS MARKET 68
4 PREMIUM INSIGHTS 69
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW 69
FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE THE KEY FACTORS DRIVING MARKET GROWTH 69
4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE & TYPE OF MANUFACTURER (2019) 70
FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2019 70
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
FIGURE 15 CHINA TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 71
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 73
5.2.1.1 Increasing incidence of chronic diseases 73
5.2.1.2 Technological advancements in API manufacturing 74
5.2.1.3 Growing importance of generics 74
TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2020 75
5.2.1.4 Increasing uptake of biopharmaceuticals 76
TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN THE US IN 2019 76
5.2.1.5 Growing adoption of AI-based tools for drug discovery 77
5.2.1.6 Adoption of organ-on-chip models in drug development 77
5.2.1.7 Focus on precision medicine 78
5.2.1.8 Investments in real-world evidence by pharmaceutical companies 78
5.2.2 RESTRAINTS 79
5.2.2.1 Unfavorable drug price control policies 79
5.2.2.2 High manufacturing costs 79
5.2.3 OPPORTUNITIES 79
5.2.3.1 Emerging biosimilars market 79
TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL IN THE US (2019–2020) 80
5.2.3.2 Highly potent active pharmaceutical ingredients 80
5.2.3.3 Emerging markets 80
5.2.3.4 Emerging technologies 81
5.2.4 CHALLENGES 81
5.2.4.1 Increasing penetration of counterfeit drugs 81

5.3 IMPACT OF COVID-19 ON THE MARKET 82
TABLE 4 INDICATIVE LIST OF COVID-19 THERAPEUTIC DRUGS IN
THE PIPELINE (CLINICAL) 82
5.3.1 COVID-19 DRUG R&D: KEY DEVELOPMENTS 83
5.3.2 COVID-19 DRUG R&D: VACCINE PRODUCTION SCENARIO, BY COUNTRY 85
5.4 VALUE CHAIN ANALYSIS 85
FIGURE 16 MAJOR VALUE IS ADDED DURING THE MANUFACTURING
AND ASSEMBLY PHASE 86
5.5 SUPPLY CHAIN ANALYSIS 86
FIGURE 17 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES 87
5.6 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET 88
FIGURE 18 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICALS MARKET 88
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 89
6.1 INTRODUCTION 90
TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 90
6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 90
6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET GROWTH 90
TABLE 6 INDICATIVE LIST OF BIOLOGICAL PRODUCTS THAT GAINED US FDA APPROVAL IN 2019 91
TABLE 7 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2020 91
TABLE 8 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018–2025 (USD BILLION) 92
TABLE 9 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 92
TABLE 10 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 92
TABLE 11 ASIA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 93
6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 93
6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 93
TABLE 12 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018–2025 (USD BILLION) 94
TABLE 13 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 94
TABLE 14 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 94
TABLE 15 ASIA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 95

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 96
7.1 INTRODUCTION 97
TABLE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 97
7.2 CAPTIVE API MANUFACTURERS 97
7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY ARE THE KEY FACTORS SUPPORTING MARKET GROWTH 97
TABLE 17 CAPTIVE API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 98
TABLE 18 NORTH AMERICA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 98
TABLE 19 EUROPE: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 99
TABLE 20 ASIA: CAPTIVE API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 99
7.3 MERCHANT API MANUFACTURERS 99
TABLE 21 MERCHANT API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 100
TABLE 22 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 101
TABLE 23 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 101
TABLE 24 ASIA: MERCHANT API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 101
7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE 102
TABLE 25 MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 102
7.3.1.1 Innovative API manufacturers 102
7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain the market growth 102
TABLE 26 INNOVATIVE API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 102
TABLE 27 NORTH AMERICA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 103
TABLE 28 EUROPE: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 103
TABLE 29 ASIA: INNOVATIVE API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 103
7.3.1.2 Generic API manufacturers 104
7.3.1.2.1 Low manufacturing cost of generics will drive the growth of this segment 104
TABLE 30 GENERIC API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 104
TABLE 31 NORTH AMERICA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 104
TABLE 32 EUROPE: GENERIC API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 105
TABLE 33 ASIA: GENERIC API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 105
7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 105
TABLE 34 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS
2018–2025 (USD BILLION) 106
7.3.2.1 Synthetic API manufacturers 106
7.3.2.1.1 Need for specialized manufacturing capabilities is driving the growth of this segment 106
TABLE 35 SYNTHETIC API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 106
TABLE 36 NORTH AMERICA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 107
TABLE 37 EUROPE: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 107
TABLE 38 ASIA: SYNTHETIC API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 107
7.3.2.2 Biotech API manufacturers 108
7.3.2.2.1 Complexity of manufacturing biotech APIs has increased the focus on partnerships between companies and CMOs 108
TABLE 39 BIOTECH API MANUFACTURERS MARKET, BY REGION,
2018–2025 (USD BILLION) 108
TABLE 40 NORTH AMERICA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 108
TABLE 41 EUROPE: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 109
TABLE 42 ASIA: BIOTECH API MANUFACTURERS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 109
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 110
8.1 INTRODUCTION 111
TABLE 43 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 111
8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 111
TABLE 44 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018–2025 (USD BILLION) 112
TABLE 45 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 112
TABLE 46 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 112
TABLE 47 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 113
8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 113
TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 113
8.2.1.1 Innovative synthetic APIs 114
8.2.1.1.1 High value of innovative APIs to drive the growth of this segment 114
TABLE 49 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018–2025 (USD BILLION) 114
TABLE 50 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 114
TABLE 51 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 115
TABLE 52 ASIA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 115
8.2.1.2 Generic synthetic APIs 115
8.2.1.2.1 Initiatives to promote the penetration of generics will drive the growth of this segment 115
TABLE 53 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2018–2025 (USD BILLION) 116
TABLE 54 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 116
TABLE 55 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 117
TABLE 56 ASIA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 117
8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 117
TABLE 57 TOP SELLING BIOLOGICS (2018) 118
TABLE 58 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2018–2025 (USD BILLION) 119
TABLE 59 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 119
TABLE 60 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 120
TABLE 61 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 120
8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 120
TABLE 62 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 121
8.3.1.1 Innovative biotech APIs 121
8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the growth of this segment 121
TABLE 63 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2018–2025 (USD BILLION) 121
TABLE 64 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 122
TABLE 65 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 122
TABLE 66 ASIA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 122
8.3.1.2 Generic biotech APIs 123
8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment 123
TABLE 67 INDICATIVE LIST OF BIOSIMILARS THAT GAINED THE US FDA APPROVAL
IN 2019 124
TABLE 68 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY REGION, 2018–2025 (USD BILLION) 124
TABLE 69 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 124
TABLE 70 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 125
TABLE 71 ASIA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 125
8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 125
TABLE 72 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 2018–2025 (USD BILLION) 126
8.3.2.1 Monoclonal antibodies 126
8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment 126
TABLE 73 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2019 127
TABLE 74 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD BILLION) 127
TABLE 75 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018–2025 (USD BILLION) 127
TABLE 76 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018–2025 (USD BILLION) 128
TABLE 77 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2018–2025 (USD BILLION) 128
8.3.2.2 Hormones & growth factors 128
8.3.2.2.1 The growing incidence of hormonal disorders will drive market growth 128
TABLE 78 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2018–2025 (USD BILLION) 129
TABLE 79 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 129
TABLE 80 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 129
TABLE 81 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 130
8.3.2.3 Cytokines 130
8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment 130
TABLE 82 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2018–2025 (USD BILLION) 130
TABLE 83 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018–2025 (USD BILLION) 131
TABLE 84 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018–2025 (USD BILLION) 131
TABLE 85 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2018–2025 (USD BILLION) 131
8.3.2.4 Fusion proteins 132
8.3.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive the growth of this segment 132
TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2018–2025 (USD BILLION) 132
TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018–2025 (USD BILLION) 132
TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018–2025 (USD BILLION) 133
TABLE 89 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2018–2025 (USD BILLION) 133
8.3.2.5 Recombinant vaccines 133
8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development—a positive indicator of growth 133
TABLE 90 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2018–2025 (USD BILLION) 134
TABLE 91 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018–2025 (USD BILLION) 134
TABLE 92 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018–2025 (USD BILLION) 135
TABLE 93 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2018–2025 (USD BILLION) 135
8.3.2.6 Therapeutic enzymes 135
8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management will drive the growth of this segment 135
TABLE 94 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2018–2025 (USD BILLION) 136
TABLE 95 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018–2025 (USD BILLION) 136
TABLE 96 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018–2025 (USD BILLION) 136
TABLE 97 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2018–2025 (USD BILLION) 137
8.3.2.7 Blood factors 137
8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment 137
TABLE 98 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2018–2025 (USD BILLION) 137
TABLE 99 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 138
TABLE 100 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 138
TABLE 101 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2018–2025 (USD BILLION) 138
8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 139
TABLE 102 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 139
8.3.3.1 Mammalian expression systems 139
8.3.3.1.1 Their ability to carry post-translational modifications will drive the market for these systems 139
TABLE 103 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018–2025 (USD BILLION) 140
TABLE 104 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 140
TABLE 105 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 140
TABLE 106 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 141
8.3.3.2 Microbial expression systems 141
8.3.3.2.1 These systems provide high expression levels of proteins, which supports their use 141
TABLE 107 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2018–2025 (USD BILLION) 141
TABLE 108 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 142
TABLE 109 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 142
TABLE 110 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 142
8.3.3.3 Yeast expression systems 143
8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand 143
TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2018–2025 (USD BILLION) 143
TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 143
TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 144
TABLE 114 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 144
8.3.3.4 Insect expression systems 144
8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand 144
TABLE 115 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2018–2025 (USD BILLION) 145
TABLE 116 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 145
TABLE 117 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 145
TABLE 118 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 146
8.3.3.5 Other expression systems 146
TABLE 119 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2018–2025 (USD BILLION) 146
TABLE 120 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY,
2018–2025 (USD BILLION) 147
TABLE 121 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 147
TABLE 122 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2018–2025 (USD BILLION) 147
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 148
9.1 INTRODUCTION 149
TABLE 123 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,
2018–2025 (USD BILLION) 149
9.2 PRESCRIPTION DRUGS 149
9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET 149
TABLE 124 PRESCRIPTION DRUGS MARKET, BY REGION, 2018–2025 (USD BILLION) 150
TABLE 125 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 150
TABLE 126 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 150
TABLE 127 ASIA: PRESCRIPTION DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 151
9.3 OVER-THE-COUNTER DRUGS 151
9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 151
TABLE 128 OVER-THE-COUNTER DRUGS MARKET, BY REGION,
2018-2025 (USD BILLION) 152
TABLE 129 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 152
TABLE 130 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 152
TABLE 131 ASIA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY,
2018–2025 (USD BILLION) 153
9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 153
9.4.1 LOW-TO-MODERATE-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 153
9.4.1.1 Higher safety, good warning properties, and lack of genic effects characterize low-to-moderate-potency APIs 153
9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 154
9.4.2.1 Most drugs under development fall into this category 154
TABLE 132 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 154
10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 155
10.1 INTRODUCTION 156
TABLE 133 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 156
10.2 COMMUNICABLE DISEASES 156
10.2.1 INCREASING GLOBAL INCIDENCE OF COMMUNICABLE DISEASES TO DRIVE MARKET GROWTH 156
TABLE 134 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2018–2025 (USD BILLION) 157
TABLE 135 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 157
TABLE 136 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 157
TABLE 137 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 158
10.3 ONCOLOGY 158
10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT THE GROWTH OF THIS SEGMENT 158
TABLE 138 INDICATIVE LIST OF THE US FDA-APPROVED DRUGS FOR ONCOLOGY (2018) 159
TABLE 139 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,
BY REGION, 2018–2025 (USD BILLION) 159
TABLE 140 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD BILLION) 159
TABLE 141 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2025 (USD BILLION) 160
TABLE 142 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,
BY COUNTRY, 2018–2025 (USD BILLION) 160
10.4 DIABETES 160
10.4.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT 160
TABLE 143 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,
BY REGION, 2018–2025 (USD BILLION) 161
TABLE 144 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018–2025 (USD BILLION) 161
TABLE 145 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2018–2025 (USD BILLION) 162
TABLE 146 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,
BY COUNTRY, 2018–2025 (USD BILLION) 162
10.5 CARDIOVASCULAR DISEASES 163
10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER 163
TABLE 147 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018–2025 (USD BILLION) 163
TABLE 148 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 163
TABLE 149 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 164
TABLE 150 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 164
10.6 PAIN MANAGEMENT 164
10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET 164
TABLE 151 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2018–2025 (USD BILLION) 165
TABLE 152 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018–2025 (USD BILLION) 165
TABLE 153 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018–2025 (USD BILLION) 165
TABLE 154 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2018–2025 (USD BILLION) 166
10.7 RESPIRATORY DISEASES 166
10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT 166
TABLE 155 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2018–2025 (USD BILLION) 167
TABLE 156 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 167
TABLE 157 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 167
TABLE 158 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2025 (USD BILLION) 168
10.8 OTHER THERAPEUTIC APPLICATIONS 168
TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2018–2025 (USD BILLION) 169
TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD BILLION) 169
TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD BILLION) 169
TABLE 162 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD BILLION) 170
11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 171
11.1 INTRODUCTION 172
TABLE 163 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,
2018–2025 (USD BILLION) 172
11.2 NORTH AMERICA 172
FIGURE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 173
TABLE 164 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY COUNTRY, 2018–2025 (USD BILLION) 174
TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 174
TABLE 166 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 174
TABLE 167 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018–2025 (USD BILLION) 175
TABLE 168 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 175
TABLE 169 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 175
TABLE 170 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 176
TABLE 171 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 176
TABLE 172 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018–2025 (USD BILLION) 176
TABLE 173 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 177
TABLE 174 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 177
TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 177
TABLE 176 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 178
11.2.1 US 178
11.2.1.1 The US is the largest market for active pharmaceutical ingredients in North America 178
TABLE 177 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 179
TABLE 178 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 179
TABLE 179 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 179
TABLE 180 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 180
TABLE 181 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
OF SYNTHESIS, 2018–2025 (USD BILLION) 180
TABLE 182 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 180
TABLE 183 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 181
TABLE 184 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 181
TABLE 185 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 181
TABLE 186 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 182
TABLE 187 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 182
TABLE 188 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 182

11.2.2 CANADA 183
11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada 183
TABLE 189 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 183
TABLE 190 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 184
TABLE 191 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 184
TABLE 192 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 184
TABLE 193 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 185
TABLE 194 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 185
TABLE 195 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 185
TABLE 196 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 186
TABLE 197 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 186
TABLE 198 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF DRUG, 2018–2025 (USD BILLION) 186
TABLE 199 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 187
TABLE 200 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 187
11.3 EUROPE 187
TABLE 201 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 188
TABLE 202 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 188
TABLE 203 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 188
TABLE 204 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 189
TABLE 205 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 189
TABLE 206 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 189
TABLE 207 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 190
TABLE 208 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 190
TABLE 209 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 190
TABLE 210 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 191
TABLE 211 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 191
TABLE 212 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 191
TABLE 213 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 192
11.3.1 GERMANY 192
11.3.1.1 Germany dominates the European active pharmaceutical ingredients market 192
TABLE 214 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 193
TABLE 215 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 193
TABLE 216 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 193
TABLE 217 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 194
TABLE 218 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 194
TABLE 219 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 194
TABLE 220 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 195
TABLE 221 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 195
TABLE 222 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 195
TABLE 223 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 196
TABLE 224 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 196
TABLE 225 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 196
11.3.2 FRANCE 197
11.3.2.1 An increase in annual pharmaceutical industry turnover will support market growth in France 197
TABLE 226 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 197
TABLE 227 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 197
TABLE 228 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 198
TABLE 229 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 198
TABLE 230 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 198
TABLE 231 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 199
TABLE 232 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 199
TABLE 233 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 199
TABLE 234 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 200
TABLE 235 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 200
TABLE 236 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 200
TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 201
11.3.3 UK 201
11.3.3.1 Rising government investments will drive the growth of the UK market 201
TABLE 238 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 202
TABLE 239 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 202
TABLE 240 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 202
TABLE 241 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 203
TABLE 242 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 203
TABLE 243 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 203
TABLE 244 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 204
TABLE 245 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 204
TABLE 246 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 204
TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 205
TABLE 248 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 205
TABLE 249 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 205
11.3.4 ITALY 206
11.3.4.1 Growing investment in API production will support market growth 206
TABLE 250 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 206
TABLE 251 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 206
TABLE 252 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018–2025 (USD BILLION) 207
TABLE 253 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 207
TABLE 254 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 207
TABLE 255 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 208
TABLE 256 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 208
TABLE 257 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 208
TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 209
TABLE 259 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 209
TABLE 260 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 209
TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 210
11.3.5 SPAIN 210
11.3.5.1 The Spanish market has been typically dominated by branded drugs 210
TABLE 262 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 210
TABLE 263 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 211
TABLE 264 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018–2025 (USD BILLION) 211
TABLE 265 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 211
TABLE 266 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 212
TABLE 267 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 212
TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 212
TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 213
TABLE 270 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 213
TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 213
TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 214
TABLE 273 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 214
11.3.6 HUNGARY 214
11.3.6.1 Rising incidence of chronic diseases will contribute to market growth 214
TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 215
TABLE 275 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 215
TABLE 276 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 215
TABLE 277 HUNGARY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 216
TABLE 278 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 216
TABLE 279 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 216
TABLE 280 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 217
TABLE 281 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 217
TABLE 282 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 217
TABLE 283 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 218
TABLE 284 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 218
TABLE 285 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 218
11.3.7 REST OF EUROPE 219
TABLE 286 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 219
TABLE 287 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 219
TABLE 288 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 220
TABLE 289 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 220
TABLE 290 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 220
TABLE 291 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 221
TABLE 292 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 221
TABLE 293 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 221
TABLE 294 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 222
TABLE 295 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 222
TABLE 296 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 222
TABLE 297 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 223
11.4 ASIA 223
FIGURE 20 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 224
TABLE 298 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 225
TABLE 299 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 225
TABLE 300 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 225
TABLE 301 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 226
TABLE 302 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 226
TABLE 303 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 226
TABLE 304 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 227
TABLE 305 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 227
TABLE 306 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 227
TABLE 307 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 228
TABLE 308 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 228
TABLE 309 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 228
TABLE 310 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 229
11.4.1 JAPAN 229
11.4.1.1 Japan dominates the Asian market for APIs 229
TABLE 311 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 230
TABLE 312 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 230
TABLE 313 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 230
TABLE 314 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 231
TABLE 315 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 231
TABLE 316 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 231
TABLE 317 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 232
TABLE 318 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 232
TABLE 319 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 232
TABLE 320 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 233
TABLE 321 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025(USD BILLION) 233
TABLE 322 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 233
11.4.2 CHINA 234
11.4.2.1 Government policies to increase medicine access and affordability will support market growth 234
TABLE 323 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 234
TABLE 324 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 235
TABLE 325 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018–2025 (USD BILLION) 235
TABLE 326 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 235
TABLE 327 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 236
TABLE 328 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 236
TABLE 329 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 236
TABLE 330 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 237
TABLE 331 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 237
TABLE 332 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 237
TABLE 333 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 238
TABLE 334 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 238
11.4.3 INDIA 238
11.4.3.1 India is a leading producer of generics 238
TABLE 335 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 239
TABLE 336 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 239
TABLE 337 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 239
TABLE 338 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 240
TABLE 339 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 240
TABLE 340 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 240
TABLE 341 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 241
TABLE 342 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 241
TABLE 343 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 241
TABLE 344 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 242
TABLE 345 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 242
TABLE 346 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 242
11.4.4 SOUTH KOREA 243
11.4.4.1 Rising annual drug exports are likely to drive market growth 243
TABLE 347 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 243
TABLE 348 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 243
TABLE 349 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 244
TABLE 350 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 244
TABLE 351 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 244
TABLE 352 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 245
TABLE 353 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 245
TABLE 354 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018–2025 (USD BILLION) 245
TABLE 355 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 246
TABLE 356 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 246
TABLE 357 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY POTENCY, 2018–2025 (USD BILLION) 246
TABLE 358 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 247
11.4.5 REST OF ASIA 247
TABLE 359 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 248
TABLE 360 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 248
TABLE 361 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 248
TABLE 362 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 249
TABLE 363 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 249
TABLE 364 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 249
TABLE 365 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 250
TABLE 366 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 250
TABLE 367 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 250
TABLE 368 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 251
TABLE 369 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,
2018–2025 (USD BILLION) 251
TABLE 370 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 251
11.5 REST OF THE WORLD 252
TABLE 371 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2018–2025 (USD BILLION) 252
TABLE 372 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 253
TABLE 373 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 253
TABLE 374 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 253
TABLE 375 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 254
TABLE 376 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 254
TABLE 377 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 254
TABLE 378 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 255
TABLE 379 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 255
TABLE 380 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 255
TABLE 381 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 256
TABLE 382 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 256
TABLE 383 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 256
11.5.1 ISRAEL 257
11.5.1.1 Financial support by the government will drive market growth 257
TABLE 384 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,
2018–2025 (USD BILLION) 257
TABLE 385 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 257
TABLE 386 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE,
2018–2025 (USD BILLION) 257
TABLE 387 ISRAEL: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 258
TABLE 388 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 258
TABLE 389 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 258
TABLE 390 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 259
TABLE 391 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY PRODUCT, 2018–2025 (USD BILLION) 259
TABLE 392 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 259
TABLE 393 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2018–2025 (USD BILLION) 260
TABLE 394 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2018–2025 (USD BILLION) 260
TABLE 395 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 260
11.5.2 OTHER COUNTRIES 261
TABLE 396 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE, 2018–2025 (USD BILLION) 261
TABLE 397 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF MANUFACTURER, 2018–2025 (USD BILLION) 261
TABLE 398 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2018–2025 (USD BILLION) 262
TABLE 399 OTHER COUNTRIES: MERCHANT API MANUFACTURERS MARKET,
BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 262
TABLE 400 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF SYNTHESIS, 2018–2025 (USD BILLION) 262
TABLE 401 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 263
TABLE 402 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2018–2025 (USD BILLION) 263
TABLE 403 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2018–2025 (USD BILLION) 263
TABLE 404 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2018–2025 (USD BILLION) 264
TABLE 405 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY TYPE OF DRUG, 2018–2025 (USD BILLION) 264
TABLE 406 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY POTENCY, 2018–2025 (USD BILLION) 264
TABLE 407 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION, 2018–2025 (USD BILLION) 265
12 COMPETITIVE LANDSCAPE 266
12.1 OVERVIEW 266
12.2 MARKET EVALUATION FRAMEWORK 266
TABLE 408 GROWTH STRATEGY MATRIX: EXPANSIONS AND COLLABORATIONS ARE THE WIDELY ADOPTED GROWTH STRATEGIES BY MARKET PLAYERS 266
12.3 COMPETITIVE SITUATION AND TRENDS 267
TABLE 409 PRODUCT LAUNCHES, JANUARY 2017−AUGUST 2020 267
TABLE 410 EXPANSIONS, JANUARY 2017−AUGUST 2020 267
TABLE 411 ACQUISITIONS, JANUARY 2017−AUGUST 2020 268
TABLE 412 AGREEMENTS, COLLABORATIONS, ALLIANCES, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2017−AUGUST 2020 268
13 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 270
13.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY 270
13.2 COMPANY EVALUATION MATRIX 270
13.2.1 STARS 270
13.2.2 EMERGING LEADERS 270
13.2.3 PERVASIVE PLAYERS 271
13.2.4 EMERGING COMPANIES 271
FIGURE 21 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET – OVERALL MARKET 271
13.3 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES 272
13.3.1 PROGRESSIVE COMPANIES 272
13.3.2 STARTING BLOCKS 272
13.3.3 RESPONSIVE COMPANIES 272
13.3.4 DYNAMIC COMPANIES 272
FIGURE 22 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - START-UPS/SMES 273
13.4 MARKET PLAYER RANKING 274
FIGURE 23 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2019 274
13.5 COMPANY PROFILES 275
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.5.1 PFIZER, INC. 275
FIGURE 24 PFIZER, INC.: COMPANY SNAPSHOT (2019) 275
13.5.2 NOVARTIS AG 279
FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT (2019) 279
13.5.3 SANOFI 282
FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019) 282
13.5.4 BOEHRINGER INGELHEIM 286
FIGURE 27 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019) 286
13.5.5 BRISTOL-MYERS SQUIBB 290
FIGURE 28 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2019) 290
13.5.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 293
FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019) 293
13.5.7 ELI LILLY AND COMPANY 295
FIGURE 30 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019) 295
13.5.8 GLAXOSMITHKLINE PLC 297
FIGURE 31 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019) 297
13.5.9 MERCK & CO., INC. 300
FIGURE 32 MERCK & CO., INC.: COMPANY SNAPSHOT (2019) 300
13.5.10 MYLAN N.V. 304
FIGURE 33 MYLAN N.V.: COMPANY SNAPSHOT (2019) 304
13.5.11 ABBVIE INC. 308
FIGURE 34 ABBVIE INC.: COMPANY SNAPSHOT (2019) 308
13.5.12 F. HOFFMANN-LA ROCHE LTD. 312
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019) 312
13.5.13 ASTRAZENECA 314
FIGURE 36 ASTRAZENECA: COMPANY SNAPSHOT (2019) 314
13.5.14 DR. REDDY’S LABORATORIES LTD. 317
FIGURE 37 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2019) 317
13.5.15 SUN PHARMACEUTICAL INDUSTRIES LTD. 322
FIGURE 38 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2019) 322
13.5.16 CIPLA, INC. 325
FIGURE 39 CIPLA, INC.: COMPANY SNAPSHOT (2019) 325
13.5.17 API PHARMA TECH 328
13.5.18 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD. 328
13.5.19 SREEPATHI PHARMACEUTICALS LIMITED 329
13.5.20 SHILPA MEDICARE LIMITED 329
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX 330
14.1 DISCUSSION GUIDE 330
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 334
14.3 AVAILABLE CUSTOMIZATIONS 336
14.4 RELATED REPORTS 336
14.5 AUTHOR DETAILS 337

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[医薬品有効成分(API)の世界市場予測(〜2025):種類別(革新型、ジェネリック)、メーカー別(キャプティブ、マーチャント)、合成別(合成、バイオテクノロジー)、製品別(ワクチン、ホルモン)、医薬品別(OTC、Rx)、用途別(糖尿病、腫瘍、CVD)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆